Journal of Cardiothoracic Surgery最新文献

{"title":"Non-absorbable running suture in coarctation repair in infants: a cross-sectional study.","authors":"Opas Satdhabudha, Manita Songvasin, Utairat Chaumrattanakul, Charinee Kantasiripitak","doi":"10.1186/s13019-025-03533-4","DOIUrl":"10.1186/s13019-025-03533-4","url":null,"abstract":"<p><strong>Background: </strong>In our institute, resection and aortic anastomosis for newborns and infants with coarctation of the aorta are typically performed using continuous nonabsorbable (polypropylene) sutures. This cross-sectional survey aims to examine the anastomosis site, focusing on the prevalence of growth and its correlation with recoarctation in cases requiring surgical reintervention.</p><p><strong>Methods: </strong>Patients who underwent aortic anastomosis for symptomatic coarctation during their first year of life between 2008 and 2023 and were still alive were included in the study for evaluation. Aortic arch diameters were assessed using computed tomography angiography (CTA), and z-scores were calculated. For patients with recurrent stenosis who required subsequent surgery, the surgical pathology was reviewed.</p><p><strong>Results: </strong>A total of 15 patients underwent CTA assessment, with a median time from surgery to CTA of 8.08 years (4.39, 10.02). The z-scores for the diameters at the repaired areas were as follows: for the distal transverse arch, the median z-score was - 0.08 (-0.52, 0.59), and for the descending aorta at the anastomosis, it was 1.13 (0.18, 1.72). When comparing the two subgroups-7 patients with aortic arch hypoplasia and 8 without-no significant differences were found in the z-scores of the diameters at the repaired sites. In one case of restenosis at the 4-year follow-up, subsequent surgery revealed that the suture line did not align with the narrowest segment.</p><p><strong>Conclusions: </strong>Using continuous non-absorbable suture for aortic anastomosis in coarctation repair for newborns and infants can result in the growth of the aortic arch and the anastomosis site reaching the normal range, regardless of the presence of aortic arch hypoplasia. Pathological findings from a surgical reintervention indicate that the aortic wall segment containing suture material does not align with the area exhibiting the greatest narrowing.</p><p><strong>Trial registration: </strong>Trial registration number (Study ID): TCTR20240412007.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"309"},"PeriodicalIF":1.5,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential auxiliary diagnostic role of pentraxin 3 in plasma and bronchoalveolar lavage fluid for pulmonary tuberculosis.","authors":"Xiufeng Huang, Hongxing Li, Lu Liu, Yu Zhang","doi":"10.1186/s13019-025-03544-1","DOIUrl":"10.1186/s13019-025-03544-1","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the auxiliary diagnostic efficacy of Pentraxin 3 (PTX3) as a biomarker for pulmonary tuberculosis (TB) by analyzing its levels in plasma and bronchoalveolar lavage fluid (BALF) in TB patients. Given the limitations of current TB diagnostic methods, the investigation also sought to evaluate the possible auxiliary help of PTX3 in distinguishing TB from other pulmonary conditions.</p><p><strong>Methods: </strong>The bioinformatic analysis utilized the Gene Expression Omnibus (GEO) dataset (GSE34608), including peripheral blood samples from individuals with TB, sarcoidosis, and healthy controls. Clinical specimens were obtained from hospitalized patients between January 2020 and March 2022, comprising 126 peripheral blood samples and 68 BALF samples. PTX3 levels were measured via enzyme-linked immunosorbent assays (ELISA), with subsequent statistical analyses conducted to assess the auxiliary diagnostic efficacy of PTX3 through ROC curve analysis.</p><p><strong>Results: </strong>The analysis of the GEO dataset revealed a notable increase in PTX3 levels in the peripheral blood of TB patients compared to controls, with an area under the curve (AUC) of 0.889. However, no significant differences in plasma PTX3 levels were observed among TB, community-acquired pneumonia (CAP), and lung cancer patients in clinical samples (AUC: 0.472). Conversely, PTX3 levels in BALF were significantly elevated in TB patients compared to individuals with CAP and lung cancer (P < 0.001), with an AUC of 0.806, along with a sensitivity of 0.800 and specificity of 0.810, suggesting its potential auxiliary diagnostic utility.</p><p><strong>Conclusion: </strong>Plasma PTX3 levels have limited diagnostic utility in distinguishing tuberculosis from other pulmonary conditions, whereas BALF PTX3 levels exhibit more possible auxiliary diagnosis ability as an auxiliary diagnostic indicator, offering a localized assessment of lung inflammation. BALF PTX3 could be a helpful adjunct in diagnosing TB, particularly in cases where conventional sputum-based tests are inconclusive. Further research is needed to validate these findings.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"308"},"PeriodicalIF":1.5,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on macrophages in cardiovascular diseases.","authors":"Minyan Zhu, Hongmei Zhou, Lei Zhou, Yaping Yang, Rong Chen","doi":"10.1186/s13019-025-03541-4","DOIUrl":"10.1186/s13019-025-03541-4","url":null,"abstract":"<p><strong>Objective and design: </strong>Cardiovascular diseases (CVD) are the leading causes of death worldwide, imposing a great burden on society. In recent years, macrophages have garnered widespread attention in CVD research. Macrophages are an important component of the body's immune system, playing a critical role in clearing pathogens, repairing damaged tissues, and regulating inflammatory responses, have the potential to serve as a potential target for the treatment of CVD.</p><p><strong>Materials and methods: </strong>To make up this review, studies covering Macrophage subtypes and signaling pathways, CVD were selected from the main medical databases.</p><p><strong>Conclusion: </strong>In CVD, macrophages can differentiate into different phenotypes(M1, M2, M4, et al.) according to their microenvironment by their plasticity and heterogeneity, release different cytokines, are regulated by multiple signaling pathways(PI3K/Akt, TLR4, TGF-β/Smads, et al.), and play other functions in CVD. M1 initiates and maintains inflammation by secreting pro-inflammatory factors, and M2 participates in the regression of inflammation and tissue repair by secreting anti-inflammatory factors. Therefore, by regulating the signaling pathway, it reduces the aggregation of macrophages, promotes the polarization of macrophages to M2, or restores M1/M2 homeostasis to improve the inflammatory microenvironment and delay CVD progression.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"307"},"PeriodicalIF":1.5,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of research on pulmonary cysts in sjögren's syndrome.","authors":"Cai-Hong Pan, Xu-Fei Zhang, Chen Chen, Xiao-Bei An","doi":"10.1186/s13019-025-03540-5","DOIUrl":"10.1186/s13019-025-03540-5","url":null,"abstract":"<p><p>Sjögren's syndrome (SS) is a chronic systemic autoimmune disease mainly involving exocrine glands and particularly affecting the salivary glands and lacrimal glands, thus inducing a dry mouth and dry eyes. Extraglandular organs are also involved in SS, and this results in damage to multiple systems. Among these, lung damage is more common, with high morbidity and mortality rates, and the lack of typical symptoms in the early stages makes it challenging to identify it. The main pulmonary manifestations of SS are bronchitis, pulmonary hypertension, pulmonary cysts, pulmonary amyloidosis, interstitial pneumonia, and pulmonary fibrosis. Cystic lung disease affects about 4-46.2% of patients with SS. The imaging characteristics of pulmonary cysts in SS, including the size, number, morphology, and distribution, as well as differential diagnosis, mechanisms underlying the formation of pulmonary cysts, and current treatment strategies, are presented in this review.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"306"},"PeriodicalIF":1.5,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12273288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of high-intensity interval training on cardiopulmonary function and quality of life in post-PCI or CABG patients with coronary heart disease: a meta-analysis.","authors":"Guizhen Hong, Fei Liu","doi":"10.1186/s13019-025-03543-2","DOIUrl":"10.1186/s13019-025-03543-2","url":null,"abstract":"<p><strong>Background: </strong>High-intensity interval training (HIIT) has emerged as a potential cardiac rehabilitation strategy for coronary heart disease (CHD) post-surgery, but its efficacy compared to moderate-intensity continuous training (MICT) remains uncertain.</p><p><strong>Aim: </strong>This meta-analysis aimed to evaluate the effects of HIIT on cardiopulmonary function and quality of life in CHD patients post-PCI or CABG in comparison with MICT.</p><p><strong>Methods: </strong>We systematically reviewed randomized controlled trials from PMID, Cochrane, Embase, Wanfang, and China National Knowledge Infrastructure (CNKI) databases comparing HIIT with MICT in CHD patients. Data on peak oxygen uptake (VO2peak), left ventricular ejection function (LVEF), heart rates, and quality of life were extracted and analyzed using random-or fixed-effects models based on heterogeneity.</p><p><strong>Results: </strong>HIIT significantly improved VO₂peak by 1.678 mL/kg/min (95%CI = 1.082-2.275), increased LVEF by 2.831% (95%CI = 1.124-4.538), enhanced peak HR by 6.717 beats/min (95%CI = 5.111-8.323) compared to MICT. Resting HR did not differ significantly between groups. Quality of life (SMD = 0.132, 95%CI = 0.051-0.213, P = 0.001) was significantly elevated by HIIT, particularly in the physical domain. Subgroup analyses showed consistent benefits of HIIT across exercise durations and times.</p><p><strong>Conclusion: </strong>HIIT effectively enhances cardiopulmonary function and quality of life in CHD post-surgery. HIIT may be a time-efficient alternative to MICT in cardiac rehabilitation programs. However, publication bias and high heterogeneity warrant caution in interpreting these results, indicating a need for further research.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"303"},"PeriodicalIF":1.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of antiangiogenic and immunotherapeutic regimens in the treatment of metastatic pulmonary lymphoepithelioma-like carcinoma.","authors":"Fu-Lian Qu, Yao-Hong Gao, Yan Zhang, Hong-Rui Zhang, Ya-Zhen Hong, Xiao-Jing Tie, Pei-Jie Liu","doi":"10.1186/s13019-025-03534-3","DOIUrl":"10.1186/s13019-025-03534-3","url":null,"abstract":"<p><strong>Background and objective: </strong>Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare histological subtype of non-small cell lung cancer for which no standard treatment protocol exists in the metastatic setting. This study aims to evaluate the efficacy and safety of antiangiogenic agents and immune checkpoint inhibitors (ICIs), individually and in combination with cytotoxic chemotherapy, in patients diagnosed with metastatic PLELC. The findings aim to inform therapeutic strategies for this uncommon malignancy.</p><p><strong>Method: </strong>A retrospective analysis of electronic medical records was performed to identify patients diagnosed with metastatic PLELC. Based on the treatment regimens received, participants were stratified into three groups: antiangiogenic agents plus ICIs (AI group), antiangiogenic agents plus ICIs and cytotoxic chemotherapy (AIC group), and antiangiogenic agents plus cytotoxic chemotherapy without ICIs (AC group).</p><p><strong>Results: </strong>Nineteen patients were included in the analysis. The overall objective response rate (ORR) was 78.9% (15/19), the disease control rate (DCR) was 94.8% (18/19), and the median progression-free survival (mPFS) was 12.9 months. In the AIC group, the ORR was 72.7% (8/11), the DCR was 90.9% (10/11), and the mPFS was 16.0 months. In the AI group, the ORR was 83.3% (5/6), the DCR was 100% (6/6), and the mPFS was 12.35 months. In the AC group, both the ORR and DCR were 100% (2/2), with an mPFS of 6.45 months. Patients in the AIC group exhibited substantial tumor regression. Furthermore, those with programmed death-ligand 1 (PD-L1) expression ≥ 50% experienced significantly prolonged mPFS compared to patients with PD-L1 expression < 50%. Following disease progression, clinical conditions remained stable under subsequent antiangiogenic therapy.</p><p><strong>Conclusion: </strong>The combination of antiangiogenic agents, ICIs, and cytotoxic chemotherapy demonstrated promising efficacy and an acceptable safety profile in the treatment of metastatic PLELC. These findings support further exploration of multi-modality regimens in this rare lung cancer subtype.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"302"},"PeriodicalIF":1.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary cardiac diffuse large B-cell lymphoma patient: clinical, histologic, immunophenotypic feature and a novel surgical technology: a case report.","authors":"Chenxi Ying, Weidong Li, Yu Zou, Bohao Dai, Xin Chen","doi":"10.1186/s13019-025-03532-5","DOIUrl":"10.1186/s13019-025-03532-5","url":null,"abstract":"<p><strong>Background: </strong>Primary cardiac lymphoma (PCL) is a rare malignancy, representing a small fraction of primary cardiac tumors. Non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL), a subtype of PCL, often presents with severe symptoms due to its cardiac involvement, and poses diagnostic and therapeutic challenges. This case highlights the use of an innovative surgical approach in managing a non-GCB primary cardiac DLBCL.</p><p><strong>Case presentation: </strong>We report the case of a 68-year-old woman presenting with palpitations, dizziness, and obstructive cardiac symptoms. Diagnostic imaging revealed a large mass in the right atrium near the superior vena cava. A novel \"zongzi\"-shaped endoscopic gauze folding technique was employed to facilitate complete tumor resection while preserving cardiac structure. Pathology confirmed double expressor DLBCL with BCL2 and MYC co-expression, indicating a high-risk profile. The patient's postoperative course was uneventful, and she was discharged in stable condition. However, follow-up imaging at six months revealed local disease progression.</p><p><strong>Conclusions: </strong>This case underscores the challenges in managing primary cardiac DLBCL and highlights the potential of novel surgical techniques to improve resection outcomes while minimizing structural damage to the heart. Further research is essential to optimize multimodal approaches, particularly for aggressive PCL subtypes like double expressor lymphoma.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"304"},"PeriodicalIF":1.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative strategies in coagulation management for cardiothoracic surgery: a narrative review of pharmacological and nonpharmacological approaches.","authors":"Aleena Ihtasham, Sahla Waqas, Muhammad Hamza, Haider Imran, Saraiba Sabar Chaudhary, Tayyaba Qayyum, Sadia Batool, Nimarta Devi, Muhammad Ali Muzammil, Malik Olatunde Oduoye","doi":"10.1186/s13019-025-03406-w","DOIUrl":"10.1186/s13019-025-03406-w","url":null,"abstract":"<p><p>The challenging management of coagulation in cardiothoracic surgery requires a multifaceted approach. The use of pharmacological interventions such as tranexamic acid, heparin, and aprotinin minimizes bleeding but increases the associated risks of renal impairment and seizures. However, aprotinin has been replaced by tranexamic acid for safety reasons. Supplementing nonpharmacological techniques, such as hemostatic agents and mechanical devices, with these pharmacological strategies can enhance surgical coagulation management. During cardiopulmonary bypass, factors such as hypothermia, acidosis, and fibrinolysis worsen coagulation disturbances, and protamine sulfate is administered for heparin reversal during the procedure. Point-of-care devices, including thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®), provide real-time monitoring of coagulation, hence guiding clinical interventions effectively, and have demonstrated a reduction in postoperative bleeding. Nonetheless, tailored approaches are critical, especially in patients with preexisting coagulation disorders as well as in pediatric surgery. Pharmacogenomics also plays a role in selecting appropriate dosages and minimizing adverse outcomes. Recent advancements in this context include novel hemostatic agents, prothrombin complex concentrates, and direct oral anticoagulants. Future research should not only explore the combined use of pharmacological and nonpharmacological strategies but also evaluate the long-term effects and cost-effectiveness of integrated approaches during cardiothoracic surgery, particularly in high-risk populations.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"305"},"PeriodicalIF":1.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of lncRNA PAX8-AS1 and miR-96-5p in non-small cell lung cancer.","authors":"Qiaoling Ying, Hui Xu, Xiaojiao Wu, Hang Fang, Jingjing Shi, Hangcheng Pan","doi":"10.1186/s13019-025-03542-3","DOIUrl":"10.1186/s13019-025-03542-3","url":null,"abstract":"<p><strong>Background: </strong>This study aims to examine the potential value of lncRNA PAX8-AS1 and miR-96-5p as diagnostic markers in non-small cell lung cancer (NSCLC). The goal is to provide a reference for improving adverse outcomes in NSCLC and developing effective early interventions in the clinic.</p><p><strong>Methods: </strong>A total of 112 NSCLC patients and 70 healthy volunteers were recruited as the study subjects. The expression levels of PAX8-AS1 and miR-96-5p were measured using fluorescence quantitative PCR. The expression levels of PAX8-AS1 and miR-96-5p were detected by fluorescence quantitative PCR. A dual luciferase reporter assay was used to detect the binding of PAX8-AS1 and miR-96-5p. ROC, Kaplan-Meier, and Cox regression analysis was used to assess the diagnostic and prognostic value of PAX8-AS1 and miR-96-5p in NSCLC.</p><p><strong>Results: </strong>In NSCLC, PAX8-AS1 was found to be downregulated, whereas miR-96-5p was upregulated. These two molecules exhibited a negative correlation and a target-binding relationship. Receiver operating characteristic (ROC) curve analysis demonstrated that PAX8-AS1 and miR-96-5p had practical diagnostic values for distinguishing NSCLC patients. Mortality increased in NSCLC patients with low PAX8-AS1 levels and decreased in those with low miR-96-5p levels. Cox regression analysis showed that PAX8-AS1 and miR-96-5p could serve as independent predictors of prognostic survival in NSCLC patients.</p><p><strong>Conclusion: </strong>PAX8-AS1 and miR-96-5p can serve as potential diagnostic biomarkers for NSCLC patients.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"299"},"PeriodicalIF":1.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nicorandil in improving angina pectoris and vascular endothelial function in elderly diabetes mellitus patients with coronary heart disease.","authors":"Ling Gao","doi":"10.1186/s13019-025-03449-z","DOIUrl":"10.1186/s13019-025-03449-z","url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical efficacy of nicorandil in treating elderly angina pectoris with diabetes mellitus (DM) and coronary heart disease (CHD), and the effect on improving vascular endothelial function (VEF).</p><p><strong>Methods: </strong>110 elderly diabetic patients with CHD and angina pectoris who were treated in our hospital from April 2019 to March 2022 were chose as samples. All the subjects were distributed into 2 groups, namely A and B, and 55 people in each. B group were treated with secondary preventive drugs for CHD, and the A group were treated with nicorandil and secondary preventive drugs for CHD. After one month, the clinical efficacy, prethrombotic state, VEF, inflammatory factor levels, cardiac function were compared.</p><p><strong>Results: </strong>The bg, DD, PAI-1, vWF, ET-1, TNF-α and hs-CRP in A group after the treatment were below those in B (P < 0.05), t-PA, FMD, The NO content was significantly exceeded that of the B group. The LVEF and RHI indexes in A were exceed the data in B (P < 0.05), and the LVEDD and LVPWd were below the data in B (P < 0.05). The effective rate of clinical treatment in A was significantly exceed B's data.</p><p><strong>Conclusion: </strong>Nicorandil can significantly improve angina pectoris in elderly patients with DM and CHD.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"295"},"PeriodicalIF":1.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}